Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q34009041

about

Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date Lenalidomide and chronic lymphocytic leukemia Ibrutinib (PCI-32765) in chronic lymphocytic leukemia Immune reconstitution in chronic lymphocytic leukemia Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia Management of elderly and unfit patients with chronic lymphocytic leukemia.Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Expanding role of lenalidomide in hematologic malignancies A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.Lenalidomide in the treatment of chronic lymphocytic leukemia.Initial treatment of CLL: integrating biology and functional status.Therapeutic advancement of chronic lymphocytic leukemia.A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.Ibrutinib: a paradigm shift in management of CLL.Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia.Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.Targeting inflammatory pathways in chronic lymphocytic leukemia.Personalized medicine in CLL: current status and future perspectives.Overview of recent developments in chronic lymphocytic leukemia.Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?What do we do with chronic lymphocytic leukemia with 17p deletion?Lenalidomide alone and in combination for chronic lymphocytic leukemia.

P2860

Q26798062-A6BFE999-6ED4-4542-B56E-B736F31925FD Q26823597-970C3C22-C258-436B-B09E-826D0B53E74F Q26852328-3C68A4CF-E909-47CD-AE88-DB2840A760BA Q26865561-4699BC29-D2E9-4362-A438-D5B038C0C2F4 Q27001318-5B20E9F7-4494-409F-B090-5CDCE34CB53F Q30243914-B2B56E97-6140-44F3-9028-60A3E8E29068 Q31056968-776AF05E-1262-4DD5-AA21-318A2D09AA76 Q33412064-0243BF09-6760-4187-827B-D68DCEE87A9C Q33418964-ABD1B059-7977-4DBB-BE0B-E975132BA2F7 Q33419580-17A33667-12A7-4B7E-8E86-A593F1B8C93A Q33423873-17620E72-33DA-4F3C-91AC-21E92C9AA099 Q33429161-2499CE3C-221E-4C85-A4AD-BC09B03CFF63 Q33796183-F595AF01-30D4-4E82-BA4E-F25157DE2459 Q33978930-DDE4336E-24C8-476C-B689-E6A5A963AA6E Q34008584-B742A0E9-D175-4F1A-B513-5D481073302E Q34172063-890DAF06-97C7-4B9C-933E-761668D0961B Q34625543-E5C8F4F3-4146-417F-BCD3-C5E935286D7A Q35592305-1A84DF57-9DA2-4D21-9B64-2E89F2022B33 Q35794593-68871CD7-1A17-4DCC-9383-25B944917612 Q35860550-1FFA5813-4ED5-4246-8B32-6CB34A19965F Q36125070-12A9A78B-F264-4BDA-955D-0DE7E019CC9B Q36219647-976BC3C9-D1B5-4D18-83AF-10F7D320B458 Q36300303-C0324F06-C7F1-4958-930C-7DE3299FB3AC Q36519986-0B938434-DEAA-4115-A843-ABD04D5AAA1D Q36715966-DFF30C03-2D73-4BA4-9E71-E2DA7C37B3E5 Q36739295-BEB55990-9746-4913-AEB4-DB9E19A8546B Q36788133-0D605D31-9B09-415B-9ED9-99E89640D46B Q36862781-3BA25F3F-DB9F-4A6C-B12A-F13FDBB3AECD Q36929831-01049684-9FF2-4E90-AE12-2830D42B3EBD Q36998431-A77A8547-4F66-4819-97DB-D6AADB153A68 Q37147789-79E0110E-9ECD-44AE-893B-2658BDDE5E3E Q37188389-82C2509C-C2B1-4551-924D-DD244DE57214 Q37351312-A208980F-A16B-4873-B4A4-9FCBD4D4E322 Q37412148-61D2694D-629F-4EC6-A178-843D6C355AFC Q37422201-83EB3494-2678-40FD-B420-4FC4429BDDE7 Q37427107-4DD67B07-46C3-4A52-8D1D-9006F511C1EC Q37958036-DC328A01-B0A4-4C66-A8D9-25F0B214F770 Q37975154-23F74EB9-ABD1-4AAB-B79F-DBA46733D428 Q38063170-0606D734-67EC-4F2C-9E35-C1997DA44BFF Q38068736-F1AB833C-EC0C-49F1-A760-F8665AC16A77

P2860

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q34009041

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

@ast

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

@en

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

@nl

type

label

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

@ast

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

@en

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

@nl

prefLabel

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

@ast

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

@en

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

@nl

P1433

Q34009041-E94C7360-AF0C-4554-9D47-3DECA777CB47

P1476

Q34009041-6AC2D9A2-2FEF-4ACB-9FB2-DFE2A04C94CC

P2093

Q34009041-1C943088-E083-44B0-856F-07565FE7EBE7

Q34009041-22493AC8-BD41-4B7E-9C50-9E7763BA80C4

Q34009041-4A196E08-0938-4AD0-9A61-AB4EBAD08C41

Q34009041-64BA4460-4523-4B54-A6D0-167BBDD827CA

Q34009041-A9C83210-2324-4FA2-864D-F5C56C73D7FD

Q34009041-B92C9898-CD8B-4877-8B57-89FED1A8E627

Q34009041-CE32FED5-BF30-412D-B38B-9395C39393E4

Q34009041-CE9BD886-44EF-49C5-B2A3-C7B9A3DD4BD4

P2860

Q34009041-06827C73-3A82-4C73-86FB-31664A842E35

Q34009041-0841BC67-3A99-402D-8996-1E4F92AB64F2

Q34009041-1230E42F-C60E-4783-AC0F-DCD4BCF200F5

Q34009041-18B032BC-227A-4C99-9A64-68DE4D5017DF

Q34009041-20D74793-EBC4-427C-8580-0152B0E1167C

Q34009041-278CAE60-2FA1-4E79-B5DB-D01E47B65C28

Q34009041-281A48F7-1267-4EAA-8E6F-025295EFB15E

Q34009041-2AC26C87-4609-42F5-8FC7-D868F08C7053

Q34009041-3564CAF7-8F9D-4A25-8C77-2D7170BAE201

Q34009041-3564CB36-233A-4DB6-9398-47CC30EDAF89

P304

Q34009041-855982DB-0215-4BF9-AB7A-39D9CB083EA4

P31

Q34009041-A0EF60D0-BFA7-4945-9B8E-57626F94AD01

P356

Q34009041-5BAE98BA-EF2D-4663-AE46-438ECB69011A

P407

Q34009041-A546EBB1-3FCD-4E06-8238-86D3B67BADA6

P433

Q34009041-37030630-F7CC-41CF-8FB3-08E4AB6DB555

P478

Q34009041-8901B93E-B2B5-40A2-9D89-00F3E29D8E41

P50

Q34009041-24CD7D05-F666-4949-9221-901541ECB245

Q34009041-B7F957C3-E768-4CD2-804E-5D35E1135855

Q34009041-CC79E112-CBC3-43B2-A430-579C54E08A8C

Q34009041-D828A2F4-DE1A-4D21-A7AA-42635CE19289

P577

Q34009041-2A9327D9-4575-4423-A479-C736E1F8E805

P5875

Q34009041-BE03F5DC-BF85-4D8C-8EDB-A854DB4AF950

P698

Q34009041-CE2F539E-4126-42F4-82F3-C52139BFE8ED

P921

Q34009041-06943D00-D79B-45ED-9B05-F638401BCB05

Q34009041-190514E6-6317-4DD0-964D-AFD09F935E33

Q34009041-FB27A57B-18F6-431C-9AF3-9A5E10502B32

P932

Q34009041-73F77C0D-406A-4271-8E09-A574E6CB2394

P356

BLOOD-2011-03-339077

P1433

P1476

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

@en

P2093

Bang-Ning Lee

http://www.w3.org/2001/XMLSchema#string

James Reuben

http://www.w3.org/2001/XMLSchema#string

Jan A Burger

http://www.w3.org/2001/XMLSchema#string

Mariela Sivina

http://www.w3.org/2001/XMLSchema#string

Sijin Wen

http://www.w3.org/2001/XMLSchema#string

Steven M Kornblau

http://www.w3.org/2001/XMLSchema#string

Susan M O'Brien

http://www.w3.org/2001/XMLSchema#string

Xavier C Badoux

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia.

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

How I treat CLL up front.

P304

3489-3498

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-03-339077

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Alessandra Ferrajoli

William G Wierda

Michael J. Keating

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51463320

http://www.w3.org/2001/XMLSchema#string

P698

21725050

http://www.w3.org/2001/XMLSchema#string

P921

P932

4123422

http://www.w3.org/2001/XMLSchema#string